AIM ImmunoTech Inc (AMEX: AIM) open the trading on Wednesday, with a bit cautious approach as it glided -7.99% to $0.24, before settling in for the price of $0.26 at the close. Taking a more long-term approach, AIM posted a 52-week range of $0.21-$0.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -2.98%. Meanwhile, its Annual Earning per share during the time was 42.86%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 45.83%. This publicly-traded company’s shares outstanding now amounts to $57.14 million, simultaneously with a float of $51.68 million. The organization now has a market capitalization sitting at $13.89 million. At the time of writing, stock’s 50-day Moving Average stood at $0.3284, while the 200-day Moving Average is $0.4001.
AIM ImmunoTech Inc (AIM) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. AIM ImmunoTech Inc’s current insider ownership accounts for 9.56%, in contrast to 14.78% institutional ownership. According to the most recent insider trade that took place on Sep 16 ’24, this organization’s CEO & President bought 5,000 shares at the rate of 0.30, making the entire transaction reach 1,515 in total value, affecting insider ownership by 1,493,042. Preceding that transaction, on Sep 13 ’24, Company’s CEO & President bought 20,000 for 0.31, making the whole transaction’s value amount to 6,160. This particular insider is now the holder of 1,488,042 in total.
AIM ImmunoTech Inc (AIM) Earnings and Revenue Records
AIM ImmunoTech Inc’s EPS increase for this current 12-month fiscal period is 45.83% and is forecasted to reach -0.32 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 25.00% through the next 5 years, which can be compared against the 42.86% growth it accomplished over the previous five years trading on the market.
AIM ImmunoTech Inc (AMEX: AIM) Trading Performance Indicators
Let’s observe the current performance indicators for AIM ImmunoTech Inc (AIM). It’s Quick Ratio in the last reported quarter now stands at 1.17. The Stock has managed to achieve an average true range (ATR) of 0.04. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 69.43.
In the same vein, AIM’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.57, a figure that is expected to reach -0.08 in the next quarter, and analysts are predicting that it will be -0.32 at the market close of one year from today.
Technical Analysis of AIM ImmunoTech Inc (AIM)
[AIM ImmunoTech Inc, AIM] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 35.85% While, its Average True Range was 0.0376.
Raw Stochastic average of AIM ImmunoTech Inc (AIM) in the period of the previous 100 days is set at 12.34%, which indicates a major fall in contrast to 24.84% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 59.60% that was lower than 78.65% volatility it exhibited in the past 100-days period.
